ClinicalTrials.gg
CompletedNCT06482177COATUpdated Jul 1, 2024

The COAT Trial: Cequa's Onset of Action Trial

A Phase 4 interventional study of Cyclosporine ophthalmic solution in Dry Eye, sponsored by Research Insight LLC. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-01.

Sponsored by Research Insight LLC · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2024, 2 years 5 months ago, and no results have been posted to the registry.
  • Registered 8 months after the study started (first participant enrolled Oct 2023, registered Jun 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies testing cyclosporine in Dry Eye Syndromes — 5 open to participants now, 5 under way, none of them phase 3. Cyclosporine · Dry Eye Syndromes.

Enrollment
20th of 41
52 · median 51
Started
2023
with 3 others
Phase 4
23 of 45
3 open now
Registered
37th of 45
by date
Lead sponsor
2 of 45
Research Insight LLC

Among the 45 studies testing cyclosporine in Dry Eye Syndromes, this one is the 20th largest by enrollment of the 41 interventional ones that give a count, is one of 4 that started in 2023, is one of 23 in phase 4, and was the 37th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

5 of the 45 studies testing cyclosporine in Dry Eye Syndromes are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About cyclosporine

Cyclosporine: first FDA approval 1983 (SANDIMMUNE), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies testing cyclosporine in Dry Eye Syndromes, or all of them as a file.
02

Study summary

Cequa's Onset of Action Trial: an Investigation of CEQUA's Speed of Onset in Improving Ocular Surface Health in Dry Eye Patients

Read the detailed description

The purpose of this study is to examine the speed of onset of CEQUA ™ in improving the ocular surface among patients with dry eye.

03

Conditions studied

  • Dry Eye

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

*Patients with the following signs: Central or inferior corneal fluorescein staining defined by the Oxford Scale Reduced tear break up time (TBUT) ≤ 10 seconds.

  • Able to comprehend and sign a statement of .
  • Willing and able to complete all required postoperative visits.

Exclusion criteria

Exclusion Criteria:

  • Ocular surgery (e.g., intraocular, oculoplastic, corneal, or refractive surgical procedure) performed within the last 3 months or at any time that in the investigator's clinical judgment if it would interfere with the outcome measures of this study.
  • ocular trauma.
  • Active ocular Herpes simplex or Herpes Zoster infection
  • Ocular inflammation (uveitis, iritis, scleritis, episcleritis, keratitis, conjunctivitis) at the discretion of the investigator.
  • Ocular infection (e.g., viral, bacterial, mycobacterial, protozoan, or fungal infection or the cornea, conjunctiva, lacrimal gland, lacrimal sac or eyelids including hordeolum/stye).
  • Active, systemic, or local disease condition that causes clinically significant ocular surface irritation such that it could interfere with the study findings.
  • Moderate to severe (Grade 2-4) allergic, vernal or giant papillary conjunctivitis.
  • Severe (Grade 3 or 4) inflammation of the eyelid (e.g., blepharochalasis, staphylococcal blepharitis or seborrheic blepharitis)
  • Eyelid abnormalities that significantly affect the lid function (e.g., entropion, ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis).
  • Ocular surface abnormality that may compromise the corneal integrity (e.g., prior chemical burn, recurrent corneal erosion, corneal epithelial defect, Grade 3 corneal fluorescein staining, map dot fingerprint dystrophy, or the effect of any other ophthalmic medication that might in the opinion of the investigator compromise the ocular surface integrity).
  • Participation in this trial in the same patient's fellow eye
  • Patients who are under age 18, pregnant or breastfeeding, or who may become pregnant during participation in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Other
    Dry Eye Disease

    Patient with dry eye disease

    Drug: Cyclosporine ophthalmic solution

Interventions

06

What researchers measure

Primary outcomes

  1. Change in corneal high order aberrations (HOA)

    Change in corneal HOA

    Time frame: After 7, 14, and 28 days of treatment

Secondary outcomes

  1. Change in corneal staining

    Corneal staining

    Time frame: After 7, 14, 28 days of treatment

Other outcomes

  1. Change in best corrected visual acuity

    Best corrected visual acuity

    Time frame: After 7, 14, and 28 days of treatment

07

Study locations

1 site
  • Harvard Eye Associates
    Laguna Hills, California 92653, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Jun 2024, 7 months.

Of 28 industry-sponsored phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 15. This study's 7 months is below that.

Counting every sponsor, half of 112 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2024
First posted
Jul 1, 2024
StartActual
Oct 12, 2023
Primary completionActual
Jun 5, 2024
CompletionActual
Jun 5, 2024
Last update
Jul 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06482177
Lead sponsor
Research Insight LLC
Responsible party
Sponsor
First posted
Jul 1, 2024
Start date
Oct 12, 2023
Primary completion
Jun 5, 2024
Completion
Jun 5, 2024
Last update
Jul 1, 2024

Study contacts

John Hovanesian, MD
principal investigator · Harvard Eye Associates

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion